Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer

− First results from SPOTLIGHT trial being presented at 2022 ASCO Genitourinary Cancers Symposium (ASCO GU) − − Totality of results support Company proceeding with New Drug Application to U.S. Food and Drug Administration – Reno, Nevada ( — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative […]

New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer

Findings shared at 2022 ASCO GU Symposium are from the first late-stage clinical study validating any gene-expression test for this patient group Reno, Nevada ( — Veracyte, Inc. announced that new data validating the clinical utility of the company’s Decipher Prostate Genomic Classifier for guiding treatment selection in men with intermediate-risk prostate cancer will be presented Thursday, February […]

New Genetic Risk Score Stratifies Lifetime Risk of Dying of Prostate Cancer in Diverse Populations

ASCO PerspectiveReno, Nevada ( — “Current prostate cancer screening recommendations rely on family history as well as race and ethnicity, factors which often don’t fully capture a person’s risk of developing or dying from prostate cancer. This new study suggests that an extensive genetic risk score could be an effective tool to guide screening decisions by […]

ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

Results confirm prolonged sustained complete response, with 71% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) having a complete remission with a median duration of response of 24.1 months By contrast, historical complete response rates for FDA-approved therapies pembrolizumab and valrubicin are of 41% and 18%, respectively1 & 2 In […]

LYNPARZA® (Olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer

Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful benefit in patients irrespective of homologous recombination repair gene mutationsReno, Nevada ( — Positive results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone […]

Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients with Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

– Late-breaking data from Cohort H of EV-103 trial to be presented at the 2022 ASCO Genitourinary Cancers Symposium – – Activity, tolerability of enfortumab vedotin support ongoing investigation in Phase 3 trials – Reno, Nevada ( — Astellas Pharma Inc. and Seagen Inc. announced the initial results from Cohort H of the EV-103 trial investigating […]